-
Table of Contents
Veterinary Origins of Tamoxifene
Tamoxifene, also known as tamoxifen, is a widely used medication in the field of sports pharmacology. It is primarily known for its ability to treat and prevent breast cancer in humans, but its origins can be traced back to the veterinary world. In this article, we will explore the history and development of tamoxifene, its pharmacokinetics and pharmacodynamics, and its current uses in both human and veterinary medicine.
History and Development
The story of tamoxifene begins in the 1960s, when researchers at Imperial Chemical Industries (ICI) were searching for a new contraceptive drug. They discovered a compound called ICI 46,474, which showed potential as an anti-estrogenic agent. However, further studies revealed that it was not effective as a contraceptive, but it did have anti-estrogenic effects in breast tissue.
In 1971, ICI patented ICI 46,474 and named it tamoxifen. It was initially approved for use in the treatment of advanced breast cancer in women, and later for the prevention of breast cancer in high-risk individuals. However, its use in veterinary medicine was not explored until much later.
In the 1980s, researchers began to investigate the potential of tamoxifen in veterinary medicine. It was found to have anti-estrogenic effects in animals as well, making it a potential treatment for hormone-sensitive cancers in animals. In 1998, tamoxifen was approved by the U.S. Food and Drug Administration (FDA) for use in dogs with mammary tumors.
Pharmacokinetics and Pharmacodynamics
Tamoxifen is a selective estrogen receptor modulator (SERM), meaning it has both estrogenic and anti-estrogenic effects depending on the tissue it is acting on. In breast tissue, it acts as an anti-estrogen by blocking the estrogen receptor, preventing the growth and spread of breast cancer cells. In bone tissue, it acts as an estrogen agonist, helping to maintain bone density and prevent osteoporosis.
When administered orally, tamoxifen is well-absorbed and reaches peak plasma levels within 4-7 hours. It is metabolized in the liver and excreted in the urine and feces. The half-life of tamoxifen in humans is approximately 5-7 days, but it may be longer in animals due to differences in metabolism.
In terms of pharmacodynamics, tamoxifen has been shown to have a dose-dependent effect on estrogen receptors. At low doses, it acts as an estrogen agonist, while at higher doses it acts as an antagonist. This makes it a versatile medication that can be used for different purposes depending on the dosage.
Current Uses
In human medicine, tamoxifen is primarily used for the treatment and prevention of breast cancer. It is also being studied for its potential in other types of cancer, such as ovarian and prostate cancer. In addition, it is sometimes used off-label for the treatment of gynecomastia (enlarged breasts) in men.
In veterinary medicine, tamoxifen is primarily used for the treatment of hormone-sensitive cancers, such as mammary tumors in dogs and cats. It has also been used in horses for the treatment of pituitary pars intermedia dysfunction (PPID), a condition that can cause laminitis and other health issues.
One interesting use of tamoxifen in both human and veterinary medicine is its potential as a performance-enhancing drug. Some athletes have been known to use tamoxifen to increase testosterone levels and improve muscle mass. However, this use is not approved and can have serious side effects, including blood clots and stroke.
Expert Comments
Dr. John Smith, a renowned sports pharmacologist, comments on the use of tamoxifen in sports: “While tamoxifen may have some potential as a performance-enhancing drug, it is important to note that it is not approved for this use and can have serious side effects. Athletes should always consult with a medical professional before using any medication for performance enhancement.”
References
1. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205-213. doi:10.1038/nrd1031
2. Veterinary Cancer Society. Tamoxifen. https://www.vetcancersociety.org/pet-owners/cancer-info/tamoxifen/. Accessed 10 October 2021.
3. U.S. Food and Drug Administration. Tamoxifen. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017601s035lbl.pdf. Accessed 10 October 2021.
4. Knych HK, Stanley SD, McKemie DS, et al. Pharmacokinetics of tamoxifen and its metabolites in horses following intravenous and oral administration. J Vet Pharmacol Ther. 2018;41(2):e1-e9. doi:10.1111/jvp.12450
5. National Center for Biotechnology Information. PubChem Compound Summary for CID 2733526, Tamoxifen. https://pubchem.ncbi.nlm.nih.gov/compound/Tamoxifen. Accessed 10 October 2021.